Drugs / HLX13
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07176650 | Nov 2025 → Dec 2026 expected | hepatocellular carcinoma | Shanghai Henlius Biotech | Recruiting | No outcome recorded |
| Phase 1 | NCT06159101 | Nov 2023 → May 2024 | — | Shanghai Henlius Biotech | Unknown | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06841185 | Apr 2025 → Jun 2027 expected | hepatocellular carcinoma | Shanghai Henlius Biotech | Not yet recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HLX13 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07176650 ↗ |
| Action | Inhibit | “anti-CTLA-4” NCT06841185 ↗ |
| Modality | Monoclonal antibody | “Recombinant anti-CTLA-4 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.” NCT06159101 ↗ |
| Route | Intravenous | “A single dose (0.3 mg/kg) of HLX13 via intravenous infusion.” NCT06159101 ↗ |
| Target | CTLA4 | “Recombinant anti-CTLA-4 fully human monoclonal antibody injection developed by Shanghai Henlius Biotech, Inc.” NCT06159101 ↗ |